https://www.selleckchem.com/pr....oducts/iwr-1-endo.ht
e unmet needs regarding individualized pain management, regardless of axSpA subgroup. To improve pneumococcal vaccination (PV) rates among rheumatology clinic patients on immunosuppressive therapy in the outpatient settings. This quality improvement project was based on the pre-post-intervention design. Phase I of the project targeted rheumatoid arthritis patients from thirteen rheumatology clinics (1/2013 to 7/2015) on immunosuppressive therapy to receive pneumococcal polysaccharide vaccine (PPSV23). In Phase II study (1/2016-10/201
Like
Comment
Share
